Roth Capital Weighs in on Natus Medical Inc.’s Q3 2016 Earnings (BABY)
Natus Medical Inc. (NASDAQ:BABY) – Equities researchers at Roth Capital decreased their Q3 2016 earnings estimates for shares of Natus Medical in a research report issued to clients and investors on Tuesday. Roth Capital analyst C. Lewis now forecasts that the brokerage will post earnings per share of $0.37 for the quarter, down from their prior forecast of $0.42. Roth Capital also issued estimates for Natus Medical’s Q4 2016 earnings at $0.49 EPS, FY2016 earnings at $1.59 EPS, Q1 2017 earnings at $0.36 EPS, Q3 2017 earnings at $0.41 EPS, Q4 2017 earnings at $0.55 EPS and FY2017 earnings at $1.75 EPS.
Natus Medical (NASDAQ:BABY) last released its earnings results on Wednesday, July 20th. The company reported $0.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.03. Natus Medical had a net margin of 10.20% and a return on equity of 13.82%. The company earned $96 million during the quarter, compared to the consensus estimate of $92.71 million. During the same quarter in the prior year, the firm earned $0.34 EPS. The company’s revenue was up 4.5% compared to the same quarter last year.
Other equities analysts also recently issued reports about the stock. Zacks Investment Research raised shares of Natus Medical from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a research note on Thursday, July 7th. Raymond James Financial Inc. raised shares of Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price target for the company in a research note on Tuesday, September 13th.
Shares of Natus Medical (NASDAQ:BABY) opened at 39.04 on Wednesday. The firm has a 50-day moving average of $40.39 and a 200-day moving average of $36.82. Natus Medical has a 52-week low of $29.54 and a 52-week high of $51.05. The stock has a market cap of $1.27 billion, a P/E ratio of 33.66 and a beta of 0.85.
Several large investors have recently bought and sold shares of BABY. Acrospire Investment Management LLC increased its stake in Natus Medical by 39.1% in the second quarter. Acrospire Investment Management LLC now owns 2,844 shares of the company’s stock worth $108,000 after buying an additional 800 shares during the period. BlackRock Inc. boosted its position in shares of Natus Medical by 36.0% in the second quarter. BlackRock Inc. now owns 3,096 shares of the company’s stock worth $117,000 after buying an additional 820 shares in the last quarter. Invictus RG purchased a new position in shares of Natus Medical during the first quarter worth about $148,000. PineBridge Investments L.P. boosted its position in shares of Natus Medical by 3.7% in the second quarter. PineBridge Investments L.P. now owns 4,200 shares of the company’s stock worth $159,000 after buying an additional 149 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its position in shares of Natus Medical by 13.9% in the second quarter. Teacher Retirement System of Texas now owns 4,602 shares of the company’s stock worth $174,000 after buying an additional 562 shares in the last quarter. 87.92% of the stock is owned by institutional investors and hedge funds.
In other Natus Medical news, insider James B. Hawkins purchased 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 28th. The stock was acquired at an average cost of $38.48 per share, with a total value of $384,800.00. Following the completion of the purchase, the insider now directly owns 459,725 shares in the company, valued at approximately $17,690,218. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.80% of the company’s stock.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Stock Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related stocks with our FREE daily email newsletter.